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Recipients Have Defects of Both Switched and IgM
Memory B Cells
Lloyd J. D’Orsogna,1 Matthew P. Wright,2 Rom G. Krueger,3 Elizabeth J. McKinnon,4
Susan I. Buffery,2 Campbell S. Witt,1,5 Nicole Staples,2 Richard Loh,6 Paul K. Cannell,2
Frank T. Christiansen,1,5 Martyn A. French1,5Allogeneic hematopoietic stem cell transplant (HSCT) recipients were assessed to elucidate memory B cell
defects underlying their increased susceptibility to infections, particularly by encapsulated bacteria. Circulat-
ing IgMmemory B cells (CD191, CD271, IgM1) and switched memory B cells (CD191, CD271, IgM2) were
enumerated in allogeneic HSCTrecipients (n 5 37) and healthy controls (n 5 35). T lymphocyte subpopu-
lations and serum levels of immunoglobulins, including IgG subclasses, and antibodies to pneumococcal poly-
saccharides were also assayed. Allogeneic HSCTrecipients were deficient in both switched memory and IgM
memory B cells compared to healthy controls (both P\.0001), irrespective of time post-HSCT. Switched
memory B cell deficiency correlated with CD41 T cell deficiency, and both correlated with serum levels
of IgG1 (P\.0001), possibly reflecting impaired B cell isotype switching in germinal centres. ‘‘Steady-state’’
serum levels of antibodies to pneumococcal polysaccharides did not correlate with circulating memory B
cells. Graft-versus-host disease (GVHD) was associated with lower IgM memory B cell counts and lower
serum levels of IgG2, IgG4, IgA, and pneumococcal antibodies. The increased susceptibility of allogeneic
HSCT patients to infection may reflect a combination of memory B cell defects, which are most common
in patients with a history of GVHD.
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Individuals who have previously received a Hema-
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with a deficiency of circulatingmemory B lymphocytes
(B cells) and serum immunoglobulins and impaired
production of antibodies to polysaccharide antigens
that may persist for many years. Affected individuals
can therefore be considered to have an acquired anti-
body deficiency disorder [1-3]. Further elucidation of
the abnormalities of B cell numbers and function un-
derlying this disorder may result in improved diagnos-
tic methods and treatments.
Streptococcus pneumoniae (pneumococcus) is the
most frequent pathogen in allogeneic HSCT patients,
and may cause severe and sometimes fatal invasive
infections months or years following transplantation,
with an incidence of up to 27% in long-term survivors
and frequent recurrences [4-6]. Pneumococcal infec-
tions following allogeneicHSCToften occur relatively
late and are 3 times more frequent than in autologous
HSCTrecipients [7]. Risk factors for invasive pneumo-
coccal disease postallogeneic HSCT include graft-ver-
sus-host disease (GVHD), splenectomy, and the use of
antithymocyte globulin (ATG) or total-body irradia-
tion (TBI) for conditioning [2,4,6,7]. However, the
immunologic defects associated with pneumococcal795
796 Biol Blood Marrow Transplant 15:795-803, 2009L. J. D’Orsogna et al.disease in these patients have not been completely
defined.
Antibody responses to capsular polysaccharide
antigens are the most impaired. For example, Nordoy
et al. [8] found that only a minority of patients
responded to vaccination with pneumococcal polysac-
charides even 4-10 years post-HSCT, despite all
patients maintaining ‘‘protective’’ serum levels of teta-
nus toxoid antibody [8]. Others have shown that ‘‘pro-
tective’’ levels of antibodies against pneumococcal
antigens decrease during the first year after transplan-
tation, regardless of serum immunoglobulin levels [3].
The opsonophagocytic activity of antibodies to pneu-
moccoal polysaccharides is also impaired [9].
In addition to pneumococci, other pathogens also
cause disease with increased frequency or severity in
HSCT recipients [10]. This has been associated with
immune defects that include low serum levels of
immunoglobulins, particularly IgG2, IgG4, and IgA,
impaired antibody responses and hyposplenism, which
are well-documented acquired immune defects in
adult and pediatric allogeneic HSCT recipients
[1,3,6,8,11,12].
Early studies revealed that the majority of circulat-
ing B cells 1 year after HSCT are naı¨ve IgD1 B cells
[13], and that such B cells lack somatic mutations in
the immunoglobulin heavy chain variable region, indi-
cating a maturational arrest [14]. Human naı¨ve B cells
exported from the bonemarrow, have aCD191CD272
IgMlowIgD1 immunophenotype, and pass through
a transitional B cell immunophenotype (CD381) prior
to becoming CD271 memory B cells [15]. The CD27
molecule has been recognized as a cell-surface marker
that identifies somatically mutated memory B cells,
which are critical for the production of protective anti-
body responses [16-18]. The human memory B cell
compartment (CD191, CD271) contains 2 subpopula-
tions; (1) IgM memory B cells (IgM1), which possess
a prediversified IgM antigen receptor and are capable
of responding immediately to the antigens of encapsu-
lated bacteria in a T cell-independent fashion [17-19];
and (2) switchedmemory B cells (IgM2), which require
T cell costimulation to produce high affinity IgG and
other isotypes of antibody within germinal centres of
lymphoid tissue [20]. Abnormal T cell-dependent B
cell responses after allogeneic-HSCTmight reflect im-
paired germinal center formation and B cell isotype
switching [21], although information is incomplete.
HSCT has been associated with a deficiency of
CD271 memory B cells, particularly in recipients
with GVHD [22,23], although it has been recently
shown that memory B cells transferred by allogeneic
bone marrow transplantation can contribute to the
antibody repertoire of the recipient [24]. Deficiency
of IgMmemory B cells in asplenic and aged individuals
has been associated with an increased susceptibility to
invasive pneumococcal disease [17]. Many otherstudies have demonstrated that abnormalities of circu-
lating memory B cell numbers also exist in a variety of
other disorders [25-28].
The aim of this study was to further characterize
the nature of the memory B cell deficiency in alloge-
neic HSCT recipients. In particular, we sought to
determine if such individuals have a deficiency of
IgM or switched memory B cells that might account
for their increased susceptibility to invasive pneumo-
coccal disease, and to determine if serum levels of
IgM, IgA, total IgG, and IgG subclasses and ‘‘steady-
state’’ IgG and IgG2 antibodies to pneumococcal poly-
saccharides are related to circulating memory B cell
numbers. We also investigated the relationship be-
tween numbers of circulating memory B cells and the
presence of GVHD, previous use of ATG and TBI,
time since transplantation, and the current circulating
T cell counts.MATERIAL AND METHODS
Patients and Controls
We undertook a cross-sectional study of 37 pa-
tients who had previously received an allogeneic
HSCT and 35 healthy controls. Informed consent
was obtained from all patients and controls. Allogeneic
HSCT recipients were at least 6months posttransplan-
tation and in remission at the time of assessment.
Patient information collected included time since
transplantation, type of allogeneic transplantation (sib-
ling or matched unrelated), previous autologous trans-
plantation, history of acute and/or chronic GVHD
(aGVHD, cGVHD), previous ATG or TBI, and sple-
nectomy. All subjects were .18 years of age. Demo-
graphic characteristics of patients and controls are
given in Table 1. Laboratory assessments were per-
formed on a single occasion between July 2005 and
August 2007.Analysis of Memory B Cells by Flow Cytometry
Leukocyteswere enriched froma10-mLperipheral
blood sample anticoagulated with ethylenediaminete-
traacetic acid (EDTA) by collecting a phosphate-buff-
ered saline (PBS)-washed buffy coat and resuspending
it in approximately 1 mL of PBS Flow Buffer contain-
ing 2% fetal calf serum (FCS). The following anti-
bodies coupled with fluoroscein isothiocyanate
(FITC), R-phycoerythrin (PE), or the tandem dye
R-phycoeythrin_cyanin 5.1 (PC5) were used for flow
cytometry; anti-CD19-PC5 (clone J4.119 Immuno-
tech, Marseille, France), anti-CD27-PE (clone IA4-
CD27 Immunotech), anti-IgM-FITC (polyclonal
fab02 Dako, Glostrup, Denmark), isotype control-PE
(clone 679.1Mc7 Immunotech), isotype control-
FITC (fab02 Dako). A total of 100 mL of diluted
Table 1. Median (IQR) Values of Total Lymphocytes and Lymphocyte Subpopulations Across Control and HSCT Groups
HSCT Patients
GVHD Years since Transplant
Controls HSCT no yes #1* >1
N 5 35 N 5 37 N 5 11 N 5 26 N 5 22 N 5 14
Male (%) 35% 54% 64% 50% 64% 43%
Age (years) 45 (27-54) 41 (33-51) 36 (31-50) 43 (36-52) 39 (33-51) 42 (35-49)
Lymphocytes (x109/L) 1.9 (1.6,2.3) 1.4 (0.9,2.2) 1.1 (1.0,2.0) 1.4 (0.9,2.2) 1.0 (0.7,1.7) 2.2 (1.3,2.7)
B cells (x106/L)
Total memory 45.8 (30.7,69.3) 7.6 (3.2,22.2) 21.0 (6.4,53.0) 6.7 (2.6,19.6) 6.4 (2.6,14.3) 21.7 (5.7,62.9)
IgM memory 18.0 (8.2,32.9) 3.2 (1.1,10.1) 10.1 (3.1,18.4) 2.4 (1.0,5.8) 2.1 (1.0,4.0) 8.7 (3.5,20.5)
Switched memory 23.6 (16.4,40.7) 5.3 (1.5,13.1) 8.0 (3.2,31.0) 4.6 (1.3,11.8) 4.2 (1.3,6.0) 13.0 (1.9,37.9)
B cells (% B cells)
Total memory 19.0 (13.2,26.2) 5.0 (2.0,9.5) 7.1 (4.0,16.6) 4.1 (1.9,7.9) 6.0 (2.1,11.8) 4.1 (2.3,7.8)
IgM memory 6.6 (3.7,12.9) 2.2 (0.9,3.7) 3.2 (1.4,4.0) 2.0 (0.7,3.0) 2.3 (0.7,4.2) 2.0 (0.9,2.6)
Switched memory 10.4 (6.9,17.4) 2.0 (0.9,5.5) 2.7 (1.8,9.9) 1.7 (0.7,5.4) 2.2 (1.3,5.5) 2.4 (0.8,5.2)
CD4 T cells (x106/L) 870 (725,1082) 320 (255,483) 407 (305,450) 298 (251,515) 316 (175,448) 385 (289,859)
CD4 T cells (% lymphocytes) 48 (42,54) 26 (21,30) 27 (26,34) 25 (15,29) 26 (23,30) 26 (20,31)
CD8 T cells (x106/L) 462 (321,658) 360 (198,616) 352 (189,542) 383 (203,702) 320 (159,474) 566 (347,699)
NK cells (x106/L) 143 (109,242) 224 (174,291) 203 (178,244) 234 (167,324) 228 (185,301) 214 (120,261)
NK indicates natural killer; GVHD, graft-versus-host disease; GVH, graft versus host; BMT, bonemarrow transplantation; HSCT, hematopoietic stem cell
transplantation.
Median value pairs in bold indicate significant differences (P < .05, Mann-Whitney U-test) when comparing either (a) HSCT patients versus controls; or
(b) among HSCT patients: (1) presence versus absence of GVH disease, or (2) sample obtained more than 1 versus <1 year since transplant.
*Five of 11 patients without GVHD and 17/26 patients with GVHD were within 1 year posttransplantation.
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perature with appropriate amounts (5 mL or 10 mL) of
the following antibodies: CD19-PC5, CD27-PE,
IgM-FITC in 1 tube, and CD19-PC5, Isotype con-
trol-PE, Isotype control-FITC in a second tube. Fol-
lowing incubation, the cell/antibody mixture was
processed in a Beckman Coulter Multi-Q_Prep instru-
ment (Fullerton, CA) to lyse the red blood cells and to
stabilize and fix the lymphocytes prior to acquisition
and analysis on the flow cytometer. Three-color data
acquisition was performed using a Beckman Coulter
XL-MCL flow cytometer with System II analysis soft-
ware or a Beckman Coulter Elite-ESP flow cytometer
with Elite analysis software. Validation data was ob-
tained on replicate samples from both instruments to
ensure reliability and comparability of data acquired
from either cytometer. B cell subpopulations were ex-
pressed as a proportion of total B cells and as a count
that was derived using the total lymphocyte count
also measured on Beckman Coulter flow cytometer.Assays of Lymphocyte Subsets and Serum
Levels of Immunoglobulins and Pneumococcal
Polysaccharide Antibodies
Flow cytometrywas used to quantify T cell popula-
tions. Natural killer (NK) cells were defined as CD16/
CD56 dual-positive cells. Serum levels of total IgG,
IgM, IgA, and IgG subclasses were assayed by nephe-
lometry in a Core Services Laboratory accredited by
the National Association of Testing Authorities
(NATA), Australia. Serum levels of total IgG and
IgG2 antibodies to pneumococcal polysaccharideswere assayed by ELISA (Binding Site, Evolis, BioRad,
Hercules, CA).Statistical Analyses
Analyses presented here consider IgM memory
and switched memory B cells as both counts and pro-
portions of total B cells. As all lymphocyte subpopula-
tion counts were derived from the total lymphocyte
count, statistically significant correlations between
subpopulation counts were only considered further if
there was also a correlation between proportions of
those subpopulations. The median and interquartile
range (IQR) are used as summary statistics. Compara-
tive analyses are nonparametric and include theMann-
Whitney U-test and Spearman’s rank correlation test.
A value of P\ .05 is considered to be significant. Anal-
yses were carried out using S-PLUS 7.0 for Windows
(Insightful Corp., Seattle, WA).RESULTS
Circulating Memory B Cells Were Depleted in
Allogeneic HSCT Recipients
We first determined if memory B cell deficiency
was evident in the HSCT recipients and if this was
because of deficiency of a particular subpopulation.
Both the counts and proportions of circulating total
memory (CD271) B cells were low in allogeneic
HSCT recipients compared with healthy controls
(P\ .0001) (Figure 1a). This depletion reflected de-
creased counts and proportions of both IgM memory
Figure 1. Allogeneic HSCT patients (n5 37) are deficient of total, IgM,
and switched memory B cells when compared with controls (n 5 35).
The plots indicate the median (thick line), interquartile range (box),
and range (whiskers) of the respective data samples.
Figure 2. Switched memory B cells correlate strongly with serum
levels of total IgG and IgG1 (P\.0001) in allogeneic HSCT patients.
798 Biol Blood Marrow Transplant 15:795-803, 2009L. J. D’Orsogna et al.(Figure 1b) and switched memory B cells (Figure 1c)
(all P\ .0001). Deficiency of memory B cell subpopu-
lations persisted in a subanalysis restricted to those re-
cipients greater than 1 year post-HSCT (P 5 .05,
switched memory B cells; P 5 .09, IgM memory B
cells).
Memory B Cell Subpopulations Correlated with
Serum Levels of IgG Subclasses and IgA But Not
Antibodies to Pneumococcal Polysaccharides
As memory B cell subpopulations were deficient in
HSCT recipients we next examined the correlation be-
tween total memory, IgM memory, and switched
memory B cells and serum levels of IgM, IgA, total
IgG, and IgG subclasses and antibodies to pneumo-
coccal polysaccharides. Switched memory B cell
counts and proportions correlated strongly with serum
levels of total IgG (r 5 .69, P\ .0001 and r 5 .6, P 5
.0007, respectively) and IgG1 (r 5 .73, P\ .0001 and
r 5 .61, P 5 .0009) (Figure 2) and less strongly with
serum levels of IgG2 (r 5 .43, P 5 .03 and r 5 .51,
P 5 .008), IgG3 (r 5 .44, P 5 .02 and r 5 .34, P 5
.09) and IgG4 (r 5 .49, P 5 .01 and r 5 .55, P 5
.004). Switched memory B cell counts and proportions
also correlated with serum levels of IgA (r 5 .50, P 5
.008 and r 5 .46, P 5 .02) but not IgM (Table 2).IgM memory B cell counts but not proportions
correlated with serum levels of total IgG, IgG1, and
IgA. Neither total IgM nor switched memory B cell
counts or proportions correlated with serum levels of
IgG or IgG2 antibodies to pneumococcal polysaccha-
rides.
Deficiency of Switched Memory B Cells and
Serum IgG Subclasses Correlated with CD41
T Cell Deficiency
Because switched memory B cell production is
dependent on CD41 T cell function we next deter-
mined if memory B cell numbers correlated with the
CD41 T cell counts. Allogeneic HSCT patients had
lower median circulating CD41T cell counts and pro-
portions than healthy controls (both P\ .0001), but
there was no difference in CD81 T cell counts (P 5
.2) (Figure 3a). CD41 T cell deficiency was less pro-
nounced but still evident in patients .1 year post-
HSCT (P5 .005). CD41T cell counts were positively
correlated with switched memory B cell counts (r 5
.66, P\ .0001) and IgM memory B cell counts (r 5
.44, P 5 .006) (Figure 3b), a finding that was substan-
tiated by positive correlations between CD41 T cell
proportions and both switched memory B cell propor-
tions (r 5 .51, P 5 .001) and IgM memory B cell pro-
portions (r 5 .41, P 5 .01) (data not shown).
CD41T cell counts correlated with serum levels of
total IgG (r 5 .64, P 5 .0003) and IgG1 (r 5 .66, P 5
.0002) (Figure 3c), and less strongly with IgG2 (r 5
.45, P 5 .02), IgG3 (r 5 .54, P 5 .005) and IgG4
(r 5 .46, P 5 .02). In contrast, CD41 T cell counts
did not significantly correlate with serum levels of
IgM, IgA or pneumococcal antibodies (Table 2).
A History of GVHDWas Associated with Lower
Serum Levels of IgG2, IgG4, IgA, and
Pneumococcal Antibodies and Lower IgM
Memory B Cells
Allogeneic HSCT recipients with GVHD carry
the highest risk of acquiring pneumococcal sepsis.
Therefore, memory B cell subpopulations and serum
levels of immunoglobulins and antibodies were com-
pared in patients with and without a history of
GVHD. Patients with a history of GVHD had lower
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Biol Blood Marrow Transplant 15:795-803, 2009 799Memory B Cells and Allogeneic HSCTserum levels of IgG2 (P5 .001) and IgG4 (P5 .01) as
well as IgA (P 5 .02) (Figure 4) and lower IgM mem-
ory B cell counts (P 5 .05) than patients without
GVHD. Furthermore, a history of GVHD was also
weakly associated with lower serum levels of IgG
and IgG2 antibodies to pneumococcal polysaccha-
rides (P5 .07 and P5 .06, respectively). Serum levels
of IgG2 antibodies to pneumococcal polysaccharides
correlated with serum IgG2 levels in all patients
(r 5 .64, P 5 .002) and GVHD patients (r 5 .55,
P 5 .03) (data not shown). A history of GVHD was
not associated with lower switched memory B cell
or CD41 T cell counts (P 5 .1 and .3, respectively)
or serum levels of IgM (P 5 .9).
Effect of TBI/ATG or Splenectomy
There was no association between previous treat-
ment with ATG or TBI and memory B cell subpopu-
lations, CD4 T cells, serum immunoglobulin levels,
or pneumococcal antibodies (data not shown). Only
1 HSCT recipient had a previous splenectomy.DISCUSSION
We have shown that allogeneic HSCT recipients
have long-term total memory B cell deficiency, con-
firming the observations of others [13,22,23], and
show for the first time that this is because of long-
term depletion of both circulating IgM memory and
switched memory B cells. We have also shown that
circulating switched memory B cell counts correlate
with serum levels of IgG subclasses and IgA, but not
IgM, and that serum levels of IgG2, IgG4, IgA, and
pneumococcal antibodies are lower in patients with
GVHD. Furthermore, switched memory B cell
counts and serum IgG subclass levels correlated
with CD41 T cell counts. Thus, we show that
HSCT patients have immune defects that impair the
reconstitution and/or generation of memory B cells,
and that these abnormalities also affect CD41 T cell
counts and the maintenance of serum IgG subclass
and IgA levels.
The 2 subpopulations of memory B cells have dis-
tinct functions. IgM memory B cells are equivalent to
marginal zone B cells of the spleen [18], which bind to
microbial cell wall polysaccharides in the circulation
and transport them to spleen germinal centers as
well as initiating an ‘‘early’’ low-affinity IgM antibody
response against the microbe. Switched memory B
cells are produced in germinal centers of lymphoid
tissues under the influence of CD41 T cells, particu-
larly follicular helper T cells (TFH cells), and migrate
to various regions of the body, including the bone
marrow, where they differentiate into plasma cells
producing high-affinity antibodies of all isotypes
[16,29]. The number of circulating IgM and switched
Figure 3. Memory B cell and IgG deficiency correlates with the CD4
T cell deficiency.
800 Biol Blood Marrow Transplant 15:795-803, 2009L. J. D’Orsogna et al.memory B cells can therefore be considered as an indi-
cator of the density and/or function of B cell marginal
zones and germinal centers, respectively, as has been
argued for primary antibody deficiency disorders [30].
Our demonstration that circulating switched
memory B cell numbers are low in HSCT patients
may therefore reflect a reduced germinal center den-
sity and/or function and impaired B cell immunoglob-
ulin isotype switching. Supporting evidence is found inFigure 4. Serum levels of IgA, IgG, and IgG subclasses are lower in
allogeneic HSCT patients with GVHD.severe combined immune deficiency (SCID) mice that
have received an allogeneic bone marrow transplant
where suboptimal antibody responses to T cell-
dependent vaccines are associated with reduced germi-
nal centre formation [21]. The effect of germinal
center density on memory B cell numbers has not
been directly studied in human allogeneic HSCT re-
cipients. In view of our demonstration that switched
memory B cell counts correlate with CD41 T cell
counts, 1 possible cause of impaired germinal center
functionmight be a deficiency of TFH cells. These cells
are present within germinal centers, and express CD4,
CCR5, and ICOS (but not CCR7) [31,32] and produce
IL-21 [31]. T cell-dependent and long-lived antibody
responses are highly dependent on the functional
properties and activity of TFH [32], and their dysregu-
lation most likely contributes to the pathogenesis of
several immunodeficiency diseases [33]. Of note, IL-
21 is a switch factor for B cells that differentiate into
plasma cells producing IgG1 [34]. Reduced IL-21 pro-
duction byTFH cells might therefore be an explanation
for the strong correlation between serum levels of
IgG1 and switched memory B cell counts demon-
strated in this study (see Figure 2).
The strong correlation of switched memory B cell
counts and CD41 T cell counts with serum IgG1 and
IgA levels suggests thatHSCT recipients have a gener-
alized impairment of T cell-dependent B cell antibody
isotype switching, in addition to the well-documented
defects of T-independent antibody responses. These
immune defects might contribute to the increased sus-
ceptibility to opportunistic infections with various
bacterial, viral, fungal, protozoan, and helminth path-
ogens in allogeneic-HSCT recipients [10].
Our finding that IgMmemory B cell numbers cor-
relate with total IgG1 and IgA was unexpected, as IgM
memory B cells are T cell-independent and do not
class switch. It has been shown in mice that IgMmem-
ory B cells shuttle between the marginal zone and fol-
licular areas of lymphoid tissue, and may function as
a link between innate and adaptive immune responses
[35,36]. This capture and follicular delivery of blood-
borne antigens is essential to the initiation of high
affinity switched memory B cell responses within the
germinal centre. Separately, it has been shown that
CD41T cell responses against pneumococcal antigens
may contribute to long-term protection against pneu-
mococcal colonization [37]. Therefore, circulating
IgM memory B cell numbers might be linked to
CD41 T cell-dependent antibody responses via their
role in delivery of antigen to follicular dendritic cells,
as suggested by others [36].
Depletion of IgM memory B cells might be a con-
sequence of hyposplenism, which occurs in up to 15%
of HSCT patients [38]. Functional hyposplenism is as-
sociated with cGVHD after allogeneic HSCT and
may occur in the absence of features of hyposplenism
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size post-HSCT can be detected by ultrasound exam-
ination and correlates with the presence of GVHD and
risk of pneumococcal sepsis [12]. Finally, Nakayama
[39] found that marginal zone reconstitution within
the splenic white pulp is delayed after human bone
marrow transplantation, and concluded that this could
be responsible for the functional asplenia of long-term
survivors.
GVHD has long been associated with an increased
risk of pneumococcal infection in HSCT patients
[4,7], but the reasons for this are unclear. The adverse
effect of GVHD on recovery of naı¨ve T cells is well
documented [40,41], and is in part related to failure
to regenerate a thymus [42]. Reduced density and/or
function of germinal centres andmarginal zones might
also be a consequence of GVHD, as well as the effects
of pretransplant conditioning [21,43]. Recipient-
derived dendritic cells (DCs) that persist and contrib-
ute to host immunity following allogeneic BMT are
a target of GVHD [44,45], and GVHD is associated
with delayed reconstitution of follicular DCs,
decreased CD221 B cells, and an inverted T cell
CD4:CD8 ratio in lymph nodes of HSCT recipients
[43]. Perivascular clusters of DCs within the bonemar-
row also provide critical survival signals to early B cells,
and ablation of these bonemarrowDCs causes a loss of
recirculating B cells [46]. Therefore, the memory B
cell deficiency we have demonstrated could also be sec-
ondary to DC dysfunction within the BM as well as in
the germinal centers of peripheral secondary lymphoid
organs. Corticosteroid and immunosuppressant ther-
apy forGVHDmay also be a factor in the pathogenesis
of B cell depletion, as patients treated with immuno-
suppressant drugs (cyclosporine, corticosteroids)
exhibit additional cytokine defects compared to non-
treated patients [47].
We have confirmed several previous observations
that HSCT patients, particularly those with GVHD,
have lower serum levels of IgG2, IgG4, and IgA
[13,48,49], and also shown that serum IgG2 levels cor-
relate with levels of IgG2 antibodies to pneumococcal
polysaccharides. Although these deficiencies might re-
flect a ‘‘recapitulation of normal B cell ontogeny’’ [48],
an alternative explanation is an acquired defect of B
cell differentiation and class switch recombination in
germinal centers. IgG2 antibodies play an important
role in the opsonophagocytic antibody response
against pneumococcal polysaccharides [50], and an
impaired ability to produce IgG2 might contribute
to the increased susceptibility to infection by pneumo-
cocci. However, it is unlikely that this is the sole cause
because IgA-deficient patients who experience an
increased susceptibility to infections have similar ab-
normalities [51], but rarely experience the overwhelm-
ing pneumococcal infections encountered by some
HSCT patients. This suggests that there are additionalimmune defects. We have shown that patients with
a history of GVHD also have fewer circulating IgM
memory B cells than patients who have not experi-
enced GVHD, which might compound the effects of
impaired production of IgG2.
Serum levels of ‘‘protective’’ antipneumococcal
antibodies decrease during the first year after HSCT
[3]. This is not associated with changes in serum im-
munoglobulin levels or vaccination history. Here, we
show that ‘‘steady-state’’ serum levels of total IgG or
IgG2 antibodies to pneumococcal polysaccharides
also show no correlation with circulating IgMmemory
or switched memory B cell numbers. This may be
because these antibodies are produced by long-lived
plasma cells [29]. Also, Lanzavecchia et al. [29] found
that tetanus-specific memory B cells, but not total
memory B cells, correlated with tetanus-specific anti-
body production in healthy controls. Therefore, it
may be more informative to examine the relationship
between pneumococcal polysaccharide-specific mem-
ory B cells and serum pneumococcal polysaccharide
antibody levels in HSCT patients.
Our finding that switched memory B cells corre-
late with CD41 T cells suggest that germinal centre
and dendritic cell function warrants further investiga-
tion in allogeneic HSCT patients. Delayed donor lym-
phocyte infusion is safe and effective at inducing graft-
versus-leukemia (GVL) effect without inducing
GVHD [52]. Furthermore, delayed infusion of donor
derived antigen specific CD41 T cells can overcome
an antigen specific T cell defect in the recipient [53].
Such infusions of donor-derived T cells may also allow
correction of a specific antibody defect via recovery of
memory B cell subpopulations. Similarly, there is now
also experience in isolating and culturing donor de-
rived DCs [54]. Allogeneic HSCT protocols that pre-
vent GVHD may reduce the risk of pneumococcal
sepsis by allowing better recovery of memory B cells.
These hypotheses could also be tested in clinical trials.
We recognize several potential limitations to this
study. Patients were sampled in a cross-sectional fash-
ion only and memory B cell numbers could not be cor-
related with a clinical outcome of pneumococcal
infection given the rarity of this condition in our allo-
geneic HSCT patient cohort, in which prophylactic
antibiotic therapy is commonly used. Also, the flow
cytometry antibody panel used to enumerate memory
B cells did not include an antibody to IgD as is now
recommended for the enumeration of circulating mar-
ginal zone B cells [30]. However, the large majority of
circulating IgM1, CD271 B cells have the characteris-
tics of marginal zone B cells [18,55], allowing us to
draw conclusions about marginal zone density and/or
function in our patient cohort.
The current study focuses on the effect of alloge-
neic-HSCT on CD271 memory B cell subpopula-
tions. Future studies could also examine the effect of
802 Biol Blood Marrow Transplant 15:795-803, 2009L. J. D’Orsogna et al.allogeneic-HSCT on transitional (CD381) B cells. If
the abnormalities observed in our study are associated
with defects in germinal centre function, as we hypoth-
esize, allogeneic HSCT should be associated with an
expansion of functionally immature transitional B
cells, as has already been found in other human immu-
nodeficiency disorders characterized by impaired
humoral immunity [15].
In conclusion, we have shown that both IgMmem-
ory and switched memory B cells are decreased in allo-
geneic HSCT recipients compared to healthy
controls. The depletion of switched memory B cells
correlated with deficiency of CD41 T cells, serum
IgG subclasses, particularly IgG1, and IgA. We sug-
gest that this might be related to impaired B cell differ-
entiation resulting from abnormal B and T cell
interactions within germinal centers. Patients with
a history of GVHD had lower numbers of IgM mem-
ory B cells as well as IgG2 deficiency and lower levels
of antibody to pneumococcal polysaccharides, which
might explain their particular susceptibility to pneu-
mococcal infection. The enumeration of circulating
memory B cell subpopulations in concert with the as-
say of serum levels of IgG subclasses, IgA and anti-
bodies to polysaccharide antigens might have clinical
utility in predicting susceptibility to infection by en-
capsulated bacteria. These findings also have
important implications for vaccination strategies in
allogeneic HSCT recipients.ACKNOWLEDGMENTS
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